companies / brenus-pharma-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-05 json
| total_raised | 23,976,00024.0M | ○ |
|---|---|---|
| founded | 2020 | |
| hq | Lyon | |
| industry | unknown | |
| stage | series-a |
Developing STC-1010, an off-the-shelf Stimulated Tumor Ghost Cells cancer vaccine designed to mimic solid-tumor heterogeneity. Targets patients with microsatellite-stable metastatic colorectal cancer who respond poorly to checkpoint inhibitors. Uses proteogenomic profiling to select cancer antigens then haptenises and inactivates the cells to drive an immune flare.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-09-17 | series-a | 23,976,00024.0M | null | ○ |
Cloudflare, Google Font API, Google Hosted Libraries, jsDelivr, cdnjs, Webflow, jquery 3.5.1
| fact | status | src |
|---|---|---|
| Series A, $24.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |